NDLI: Small non-coding RNA signature in multiple sclerosis patients after treatment with interferon-β

Content Provider	Springer Nature : BioMed Central
Author	De Felice, Bruna Mondola, Paolo Sasso, Anna Orefice, Giuseppe Bresciamorra, Vincenzo Vacca, Giovanni Biffali, Elio Borra, Marco Pannone, Raimondo
Abstract	Background Non-coding small RNA molecules play pivotal roles in cellular and developmental processes by regulating gene expression at the post-transcriptional level. In human diseases, the roles of the non-coding small RNAs in specific degradation or translational suppression of the targeted mRNAs suggest a potential therapeutic approach of post-transcriptional gene silencing that targets the underlying disease etiology. The involvement of non-coding small RNAs in the pathogenesis of neurodegenerative diseases such as Alzheimer’s , Parkinson’s disease and Multiple Sclerosis has been demonstrated. Multiple sclerosis (MS) is an autoimmune disease of the central nervous system, characterized by chronic inflammation, demyelination and scarring as well as a broad spectrum of signs and symptoms. The current standard treatment for SM is interferon ß (IFNß) that is less than ideal due to side effects. In this study we administered the standard IFN-ß treatment to Relapsing-Remitting MS patients, all responder to the therapy; then examined their sncRNA expression profiles in order to identify the ncRNAs that were associated with MS patients’ response to IFNß. Methods 40 IFNß treated Relapsing-Remitting MS patients were enrolled. We analyzed the composition of the entire small transcriptome by a small RNA cloning method, using peripheral blood from Relapsing-Remitting MS patients at baseline and 3 and 6 months after the start of IFNß therapy. Real-time qPCR from the same patients group and from 20 additional patients was performed to profile miRNAs expression. Results Beside the altered expression of several miRNAs, our analyses revealed the differential expression of small nucleolar RNAs and misc-RNAs.For the first time, we found that the expression level of miR-26a-5p changed related to INF-β response. MiR-26a-5p expression was significantly higher in IFN-β treated RRMS patients at 3 months treatment, keeping quite stable at 6 months treatments. Conclusions Our results might provide insights into the mechanisms of action of IFN-β treatment in MS and provide fundamentals for the development of new biomarkers and/or therapeutic tools.
Related Links	https://bmcmedgenomics.biomedcentral.com/counter/pdf/10.1186/1755-8794-7-26.pdf
Ending Page	9
Page Count	9
Starting Page	1
File Format	HTM / HTML
ISSN	17558794
DOI	10.1186/1755-8794-7-26
Journal	BMC Medical Genomics
Issue Number	1
Volume Number	7
Language	English
Publisher	BioMed Central
Publisher Date	2014-05-17
Access Restriction	Open
Subject Keyword	Human Genetics Microarrays Gene Expression Multiple sclerosis IFN-β sncRNA microRNA snorRNAs
Content Type	Text
Resource Type	Article
Subject	Genetics (clinical) Genetics
Journal Impact Factor	2.1/2023
5-Year Journal Impact Factor	2.5/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Small non-coding RNA signature in multiple sclerosis patients after treatment with interferon-β

MicroRNA Expression Changes during Interferon-Beta Treatment in the Peripheral Blood of Multiple Sclerosis Patients (2013)

Small Non-Coding RNAs in the Human Placenta: Regulatory Roles and Clinical Utility

MicroRNA Expression Changes during Interferon-Beta Treatment in the Peripheral Blood of Multiple Sclerosis Patients

Erythrocyte microRNA sequencing reveals differential expression in relapsing-remitting multiple sclerosis

Biomarker discovery: quantification of microRNAs and other small non-coding RNAs using next generation sequencing

Identification of the ferroptosis-related long non-coding RNAs signature to improve the prognosis prediction and immunotherapy response in patients with NSCLC

Impacts of heavy smoking on non-coding RNA expression for patients with esophageal carcinoma

Integration analysis of long non-coding RNA (lncRNA) role in tumorigenesis of colon adenocarcinoma

Small non-coding RNA signature in multiple sclerosis patients after treatment with interferon-β

Similar Documents

Small non-coding RNA signature in multiple sclerosis patients after treatment with interferon-β

MicroRNA Expression Changes during Interferon-Beta Treatment in the Peripheral Blood of Multiple Sclerosis Patients (2013)

Small Non-Coding RNAs in the Human Placenta: Regulatory Roles and Clinical Utility

MicroRNA Expression Changes during Interferon-Beta Treatment in the Peripheral Blood of Multiple Sclerosis Patients

Erythrocyte microRNA sequencing reveals differential expression in relapsing-remitting multiple sclerosis

Biomarker discovery: quantification of microRNAs and other small non-coding RNAs using next generation sequencing

Identification of the ferroptosis-related long non-coding RNAs signature to improve the prognosis prediction and immunotherapy response in patients with NSCLC

Impacts of heavy smoking on non-coding RNA expression for patients with esophageal carcinoma

Integration analysis of long non-coding RNA (lncRNA) role in tumorigenesis of colon adenocarcinoma

Small non-coding RNA signature in multiple sclerosis patients after treatment with interferon-β